We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Nanopore Technologies Plc | LSE:ONT | London | Ordinary Share | GB00BP6S8Z30 | ORD GBP0.0001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 6.25 | 6.49% | 102.50 | 973,895 | 16:35:23 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 101.80 | 102.40 | 102.90 | 96.30 | 96.30 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 169.67M | -154.51M | -0.1798 | -5.67 | 875.83M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 18:28:27 | O | 624 | 101.69 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/4/2024 | 13:00 | UK RNS | Oxford Nanopore Technologies plc Study unlocks insights into disease and.. |
| 12/4/2024 | 12:00 | UK RNS | Oxford Nanopore Technologies plc LTIP and DBP; Director/PDMR Notification |
| 11/4/2024 | 16:00 | UK RNS | Oxford Nanopore Technologies plc Share Incentive Plan - Director/PDMR.. |
| 08/4/2024 | 16:00 | UK RNS | Oxford Nanopore Technologies plc Block Listing Interim Review |
| 02/4/2024 | 14:00 | UK RNS | Oxford Nanopore Technologies plc Issue of Equity and Total Voting Rights |
| 28/3/2024 | 17:55 | UK RNS | Oxford Nanopore Technologies plc Holding(s) in Company |
| 12/3/2024 | 16:00 | UK RNS | Oxford Nanopore Technologies plc Share Incentive Plan - Director/PDMR.. |
| 12/3/2024 | 07:00 | UK RNS | Oxford Nanopore Technologies plc Oxford Nanopore to Present at Barclays.. |
| 08/3/2024 | 12:00 | UK RNS | Oxford Nanopore Technologies plc Director/PDMR Shareholding |
| 07/3/2024 | 12:39 | ALNC |  DIRECTOR DEALINGS: Oxford Nanopore Technologies top team buys shares |
Oxford Nanopore Technolo... (ONT) Share Charts1 Year Oxford Nanopore Technolo... Chart |
|
1 Month Oxford Nanopore Technolo... Chart |
Intraday Oxford Nanopore Technolo... Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/4/2024 | 16:44 | OXFORD NANOPORE | 1,318 |
| 10/5/2004 | 09:41 | Ј8m boost for Online Travel | 473 |
| 29/1/2004 | 21:48 | Online Travel - Superb chart and fundamentals | 3 |
| 19/12/2003 | 17:11 | ONT - 4 new contracts worth Ј7million | 310 |
| 15/10/2003 | 03:30 | Online Travel Corporation | 962 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-23 17:28:27 | 101.69 | 624 | 634.55 | O |
| 2024-04-23 17:09:06 | 101.81 | 31 | 31.56 | O |
| 2024-04-23 17:07:33 | 100.39 | 10,027 | 10,066.21 | O |
| 2024-04-23 16:51:11 | 99.25 | 1 | 0.99 | O |
| 2024-04-23 16:51:11 | 102.50 | 125 | 128.13 | O |
| Top Posts |
|---|
Posted at 23/4/2024 09:20 by Oxford Nanopore Technolo... Daily Update Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 96.25p.Oxford Nanopore Technolo... currently has 859,503,324 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £875,833,887. Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -5.67. This morning ONT shares opened at 96.30p |
Posted at 22/4/2024 11:58 by brucie5 "Non pasaran!"Well maybe. Small buys look like being soaked up. Anyone with level 2 access care to share what they see this morning? My conjecture continues to be that this is capitulation. I'm surprised that anyone left in would be still trying to sell. As yet nothing to send the share the other way, except some correction of the oversold situation on the chart. The 50sma, with which the share price not infrequently makes contact on the way down is at 1.30p. So best guess is that we could see a 25% correction the other way without even touching the current trend. In the medium term I continue to look for the recapturing of the £1 level before we see a credible base begin to build. All on the tea leaves, obviously, so NAI. |
Posted at 13/4/2024 12:27 by 74tom Last few thoughts from me for now;1. The decline has been driven by low volume, with the average daily value of shares traded in 2024 sitting at £2m (2021 was £12.7m, 2022 was £5.4m and 2023 was £3m). A bottom normally forms when volume is high, so there is no capitulation from large shareholders, it's just a sustained downward pressure. 2. The heavy shorting of US listed arch rival Pacbio is undoubtedly influencing ONT's share price. From my research there appears to be a significant chance of them becoming insolvent, with their market cap of $844m exceeded by $892m of Convertible note debt, and cash of $631m declining by ~$80m per quarter. Cumulative shares held short were 49m at 28th March, which is ~18% of it's float, up from 10% this time last year. Conversely to ONT, PACB has sold off on significantly higher than average volume, as you can see from @Bamboo2,s chart above. It will be very interesting to see how things play out this year, if PACB are commercially impaired then it can only be a good thing for ONT in my opinion. |
Posted at 23/3/2024 12:01 by bamboo2 Price action is far from ideal.This is a weak sector at present. Hopefully it should change at some point, as massive expansion of sequencing around the world is forecast. The UK market is discounting many growth and tech stocks, and analysts have taken against ONT management and their attempts to be realistic in the face of unexpected problems, such as the ban on export of devices containing NVDA chips to China. On the positive side, ONT has almost completed the planned increases of staff in technical, manufacturing and sales functions. Naturally, this should increase turnover. Accuracy continues to improve and customer sentiment is at all time highs. The new ASIC should get an airing in May 2024. Management have so far made no attempt to extend the life of LAT shares that expire in June 2024, which means takeover potential could lift the valuation. There are a large number of organisations around the world that could currently buy the whole company for pocket money. I find ONT one of the most exciting companies in the UK, and despite a losing position at present will continue to hold for the long term. |
Posted at 22/3/2024 16:53 by minsky x = ONT share price;while x > 0 { bamboo2 posts article about ONT success; x = x-2; } |
Posted at 04/3/2024 16:20 by 74tom Quite extraordinary to think that the EV here is now ~£600mI do think the recent accelerated decline is mainly due to PACB's share price performance. Today, at fresh 1 year lows, they have a market cap of $1.29b. At 31/12 they had $631.4m of cash & $891m of CLN debt, so their EV was $1.549b, which is around double that of ONT. If you compare the financial performance of each company, ONT is far superior. PACB grew top line product revenue by 69% YoY, however this translated to a pathetic 8% improvement in gross profit from $49m to $52m. Operating losses were $334m on gross margins of 26%... ONT's gross margins are more than double at 57%, and their H123 gross profit was greater than PACB's entire FY23 number. Hard to fathom how ONT can remain on LSE much longer. |
Posted at 04/12/2023 19:47 by bamboo2 Some detective work on the remainder of the Woodford holding [formerly the Woodford Patient Capital Trust holding] which is now managed by Schroders under the ticker INOV.Nortrust Nominees Limited A/C WIZ02(7) Prior to admission 25,927,100 3.65% Post admission 23,334,390 2.94% Beneficial interest in these Ordinary Shares was held by Schroder UK Public Private Trust plc under the ticker SUPP, now known as INOV. Day/mth/yr Holding value ONT share price quantity held 31/12/2022 £56,529,000 2.466 = 22,923,357 30/06/2023 £44,000,000 2.132 = 20,599,250 30/09/2023 £42,100,000 2.056 = 19,990,272 Therefore, at eod on 30/9/2023 INOV held 2.33% They are committed to 'rebalancing' their portfolio, so I expect the selling to continue. |
Posted at 10/11/2023 08:56 by bamboo2 This paper goes a long way to explaining why the ongoing UK clinical trial of Illuminas GRAIL should be shown the door, because it is ineffective, slow, expensive and outdated compared with ONT's long read capability.==================== Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing. The paper explained Problem Current sequencing methods based on short-read technologies to analyze cell-free DNA (cfDNA) as a liquid biopsy in cancer patients have limitations. These include a bias toward shorter cfDNA populations and long waiting times for data. The Oxford Nanopore Technologies (ONT) platform offers a portable and fast alternative, capable of sequencing any length of cfDNA fragment. However, its potential for analyzing cfDNA from cancer patients remains underexplored. Results Plasma and urine samples from lung and bladder cancer patients, as well as healthy controls, were sequenced with a MinION ONT and compared to a short-read sequencer. The ONT platform successfully retrieved cfDNA somatic copy number aberrations within 24 h of sampling, and with comparable sensitivity to short-read technologies. The study also demonstrated that ONT sequencing could recover long cfDNA fragments in both plasma and urine samples, contrary to the canonical belief that cfDNA is predominantly short and fragmented. The presence of tumor-derived signal in these long fragments is confirmed in not only humans but also using a xenograft model. In addition to the size profile, other fragmentomic features could be retrieved from the cfDNA data. Impact In conclusion, the ONT sequencing provided a fast and accurate analysis of cfDNA from liquid biopsy samples. It allowed the detection of copy number aberrations, estimation of tumor fraction, and recovery of long cfDNA fragments. The ONT platform's deployability and short turnaround time make it a promising tool for liquid biopsy analysis. |
Posted at 19/10/2023 07:56 by bamboo2 BioMérieux makes strategic investment in Oxford Nanopore19 October 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Oxford, UK and Marcy-l'Étoile, France, 19 October 2023. Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics ("IVD") today announce that bioMérieux is making an immediate GBP70M investment in Oxford Nanopore. In addition, bioMérieux expects to make further market purchases of Oxford Nanopore's shares from time to time, up to a further 3.5% of Oxford Nanopore's shares, subject to availability and price. The investment strengthens the relationship between the two companies, further aligning with Oxford Nanopore's increasing focus on clinical markets through a partnership announced in April this year. This investment will support development for products in Oxford Nanopore's portfolio to serve IVD markets in conjunction with bioMérieux's commitment to advancing global public health. Through this partnership and this investment, the two companies intend to leverage Oxford Nanopore's ground-breaking nanopore-based IVD solution and bioMérieux's IVD expertise in R&D, Regulatory, Medical and Market Access. As part of the transaction, the two companies will establish an IVD Advisory Board to advance nanopore technology into routine clinical use. Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. The unique real-time, scalable features and advances in single-nucleotide sequencing accuracy of this technology make it ideal for the rapid and cost-effective characterization of pathogens in clinical samples. Together, the companies are driving to meet a significant unmet need in the clinical and diagnostic markets- an opportunity where nanopore sequencing is uniquely suited to deliver impact where information-rich, rapid, accessible, and affordable sequencing are critical. Oxford Nanopore reconfirms its guidance to be adjusted EBITDA breakeven by the end of 2026. Gordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer, commented: "With bioMérieux's strategic investment and our shared commitment to innovation, we are poised to accelerate the development of nanopore-based IVD solutions. This investment will enable us to deliver rapid, accessible, and affordable clinical tools more quickly to address unmet needs and improve healthcare worldwide." Pierre Boulud, bioMérieux CEO, commented: "This investment will reinforce our existing partnership with Oxford Nanopore and provide more resources for the development of innovative IVD solutions. Drawing on our six decades of expertise in the in vitro diagnostic space, we consider that the new generation of sequencing technology developed by Oxford Nanopore holds promise to answer future diagnostic needs and will further improve patient care, in particular against the ever-growing infectious diseases threat." Transaction structure -- bioMérieux has agreed to subscribe for 29,025,326 ordinary shares (which equates to 3.5% of Oxford Nanopore's voting rights as at 13 October 2023) in Oxford Nanopore at a subscription price of 238.08p per share (the "Subscription"), conditional only upon Admission (as defined below) occurring. This represents a total investment of nearly GBP70 million. -- Applications will be made to the Financial Conduct Authority and the London Stock Exchange for the shares issued pursuant to the Subscription to be admitted to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange ("Admission"). -- Admission is expected to occur on Monday 23 October 2023. -- The Subscription price of 238.08p per share is equal to the 6-month volume weighted average price as at 13 October 2023. As part of the Subscription, subject to certain customary exceptions, bioMérieux undertakes to: -- For a period of 5 years, not acquire or agree to acquire any interests in Oxford Nanopore's shares which would result in it and its affiliates having an interest exceeding 9.9% of the issued share capital of Oxford Nanopore (provided that this restriction shall be suspended for so long as Oxford Nanopore is in an offer period (included in the Definitions of the City Code on Takeovers and Mergers (the "Code")), and in the case of an offer period which is commenced by an announcement under Rule 2.4 of the Code, for a one month period after the cessation of such offer period); -- not dispose of any shares in Oxford Nanopore for 12 months, subject to certain limited exceptions; and -- comply with certain orderly marketing obligations for a period of four years after expiry of the 12-months lock-up period, subject to certain limited exceptions. |
Posted at 19/6/2023 11:35 by scrutable 74tomMany lab workers will inevitably resist change from ILL to ONT even where it is an obviously better process. ONT presages loss of work. For some types of short code work it won't matter much and ILL will still have an economic edge. The least busy labs will resist change. That's normal. Forking out for the ONT kit will deter many where the volume of such work is low. The ILL share price was in continuous fall for 12 months from June 2021 since when the trend channel has only flat lined. .An investment in ONT has, for the last three months, shown escalating advantage over ILL, which can resist this divergence by beginning to pay a dividend - but this would only stave off the inevitable. ILL will soon be 'yesterday's share unless it exploits the financial power of Wall Street to effect a takeover of ONT which must already be being considered as a survival strategy. The UK does not have many global leaders. Our crown jewels are always underpriced |
Posted at 14/6/2023 13:31 by scrutable Too much is being deduced from reading the tea leaves.News flow makes it clear that the company is, in the real world of achievement and potential, accelerating, and now surpasses PAC and ILL. This re-raises the old semantic confusion between Share Price and Value. ONT's share price has tested enough FOMO during the last three months of unchecked share price rise to tempt traders to take profits, leaving LT holders less worried. Last week's steady share price reversal from 272p totalling 40p reflects Fibonacci's marvellous insight into crowd behaviour and has just reached the point of inflection having fallen around 40% of the last 102p share price rise. Theory expects an imminent return to share price escalation. Let's see what happens to test the theory. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
